
---
title: '抗原检测试剂获大面积使用，市场规模或超2000亿元，19家公司产品已获批。一季报行情启动，6股年报、一季报净利润均翻倍（附股）'
categories: 
 - 金融
 - 证券时报网
 - 数据
headimg: 'https://data.stcn.com/djsj/202203/W020220328280953301283.png'
author: 证券时报网
comments: false
date: Mon, 28 Mar 2022 07:39:00 GMT
thumbnail: 'https://data.stcn.com/djsj/202203/W020220328280953301283.png'
---

<div>   
<p><strong>上海开展新一轮核酸筛查</strong></p><p><strong>抗原检测已逾1400万人</strong></p><p>3月27日，据“上海发布”微信公众号消息，为遏制疫情扩散蔓延势头，保障人民群众生命安全和身体健康，尽快实现社会面动态清零，综合前几轮核酸筛查情况并经专家评估研判，市新冠肺炎疫情防控工作领导小组研究决定，在全市范围内开展新一轮切块式、网格化核酸筛查。</p><p>在同日的疫情防控工作新闻发布会上，上海市卫健委一级巡视员吴乾渝针对全市非重点区域开展的抗原检测进展情况进行介绍。她表示，目前全市已抗原检测1400多万人，还将继续开展。从中发现一些抗原检测阳性人员，立即对其进行核酸检测与管控，抗原检测速度快、操作简便的优势得到了体现。</p><p>3月11日，随着国家卫健委印发《新冠病毒抗原检测应用方案（试行）》，新冠抗原检测试剂正式在国内获批。截至3月23日，国家药监局已先后批准19个新冠病毒抗原检测试剂产品。</p><p style="text-align: center;"><img src="https://data.stcn.com/djsj/202203/W020220328280953301283.png" title="WechatIMG1499.png" alt="WechatIMG1499.png" width="500px" height="266.6666666666667px" style="width: 500px; height: 266.667px;" oldsrc="W020220328280953301283.png" referrerpolicy="no-referrer"></p><p><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS601878" code="601878">浙商证券</a>认为，当前的全球优势毒株奥密克戎具有传染性强、潜伏期短的特点，因此抗原检测将作为核酸检测的重要补充得到推广。试剂采取了政府指导价，其核心目的是促进尽早大规模应用，抗击疫情，重点在于“放量”而非“限价”。同时相关政策及各地尤其是疫情严重地区的大规模使用标志着应用场景正加速打开，整体来看市场仍有较大潜力。</p><p><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600918" code="600918">中泰证券</a>表示，参考海外发放政策，预测国内单月市场规模或达到177-266亿元。如考虑到居民、企业自费购买情况，预计新冠抗原检测产品采购需求有望进一步提升。</p><p>证券时报·数据宝梳理了新冠抗原检测产品产业链个股名单，21股上榜。其中相关业务为“抗原检测”的个股即为旗下抗原检测试剂已获国家药监局批准的上市公司，共计10家。3月至今，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002932" code="002932">明德生物</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688298" code="688298">东方生物</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603392" code="603392">万泰生物</a>3只抗原检测股齐齐涨逾7%；4只药房股则集体回调，跌幅均逾12%。</p><p style="text-align: center;"><img src="https://data.stcn.com/djsj/202203/W020220328279675401562.png" uploadpic="https://rmy.stcn.com/webpic/W0202203/W020220328/W020220328279675401562.png" title="新冠抗原检测产品产业链个股.png" alt="新冠抗原检测产品产业链个股.png" width="500px" height="457.2072072072072px" style="width: 500px; height: 457.207px;" oldsrc="W020220328279675401562.png" referrerpolicy="no-referrer"></p><p>以年报/预告区间中值计算，大部分检测股全年业绩高增。<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688068" code="688068">热景生物</a>净利润同比呈18倍以上增长，另有<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002432" code="002432">九安医疗</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300942" code="300942">易瑞生物</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300406" code="300406">九强生物</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603392" code="603392">万泰生物</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002932" code="002932">明德生物</a>和<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688298" code="688298">东方生物</a>6股全年净利润翻倍。机构对于<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603939" code="603939">益丰药房</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002727" code="002727">一心堂</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688105" code="688105">诺唯赞</a>等个股关注度较高，评级机构均在15家以上。</p><p><strong>6股年报、一季报净利润均成倍增长</strong></p><p>三月将尽，一季报预增行情悄然拉开序幕。数据宝统计，上周五盘后至今，18股先后发布2022年第一季度业绩预告。从预告类型看，仅<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300322" code="300322">硕贝德</a>一股为预减，其余均为预增或略增。以预告区间中值计算，8股净利润同比有望翻倍。<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000762" code="000762">西藏矿业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600438" code="600438">通威股份</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600141" code="600141">兴发集团</a>稳坐三甲席位，净利润增幅均逾370%；其后<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300363" code="300363">博腾股份</a>和<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600063" code="600063">皖维高新</a>净利润增幅均在190%以上。</p><p style="text-align: center;"><img src="https://data.stcn.com/djsj/202203/W020220328280953357012.png" title="周末发布2022年第一季度业绩预告个股.png" alt="周末发布2022年第一季度业绩预告个股.png" width="500px" height="376.32042253521126px" style="width: 500px; height: 376.32px;" oldsrc="W020220328280953357012.png" referrerpolicy="no-referrer"></p><p></p><p style="text-align: center;"></p><p><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000762" code="000762">西藏矿业</a>表示，报告期内，公司锂盐产品销量提升，锂利润大幅增长带动业绩大幅上升；<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600438" code="600438">通威股份</a>称，由于光伏装机超预期，多晶硅需求旺盛，公司产品量价齐升，进而实现一季度量利双增；<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600141" code="600141">兴发集团</a>则受益于行业持续高景气以及参股项目陆续建成投产，净利润同比大幅增加。<br></p><p>行情方面，7股最新价较年内高点回撤逾20%，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300322" code="300322">硕贝德</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000762" code="000762">西藏矿业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688383" code="688383">新益昌</a>回撤已逾25%；估值方面，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600219" code="600219">南山铝业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603966" code="603966">法兰泰克</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS605006" code="605006">山东玻纤</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600063" code="600063">皖维高新</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600141" code="600141">兴发集团</a>最新滚动市盈率较低，均不足15倍；机构关注度方面，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603605" code="603605">珀莱雅</a>评级机构家数断层居首，多达43家；<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600438" code="600438">通威股份</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ301071" code="301071">力量钻石</a>和<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603613" code="603613">国联股份</a>获20家以上机构参与公司评级。</p><p>值得注意的是，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600141" code="600141">兴发集团</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688779" code="688779">长远锂科</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000762" code="000762">西藏矿业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ301071" code="301071">力量钻石</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688690" code="688690">纳微科技</a>和<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600438" code="600438">通威股份</a>6股2021年度和今年一季度业绩均呈现高增长，净利润同比增幅均在100%以上。其中<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600141" code="600141">兴发集团</a>与<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000762" code="000762">西藏矿业</a>表现最好，年报和一季报净利润同比增幅双双突破370%。（数据宝 张智博）</p><p>声明：数据宝所有资讯内容不构成投资建议，股市有风险，投资需谨慎。</p>
  
</div>
            